| Literature DB >> 17667218 |
Sarabjeet Singh1, Meenakshi Verma, Amol Bahekar, Preeti Agrawal, Jasleen Duggal, Maria Iliescu, Pam Khosla, Shirin Muzaffar.
Abstract
Enoxaparin, a low-molecular-weight heparin used to treat and prevent deep venous thrombosis, has been evaluated in several clinical trials. Thrombosis induced by enoxaparin with no evidence of heparin-induced thrombocytopenia (HIT) is seldom described. We report a rare case in which an 89-year-old African-American female developed large, multiple, painful lesions induced by enoxaparin administration. Laboratory investigations for HIT, disseminated intravascular coagulation, protein C, protein S, factor V, factor VIII, antithrombin III, and homocysteine deficiency were negative. Unfortunately, despite aggressive management for 2 weeks, the patient developed severe sepsis and died.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17667218 DOI: 10.1097/MJT.0b013e3180325905
Source DB: PubMed Journal: Am J Ther ISSN: 1075-2765 Impact factor: 2.688